Effects of a high-fat, high-cholesterol diet on brain lipid profiles in apolipoprotein E e{open}3 and e{open}4 knock-in mice

Neurobiology of Aging

Volumn 34, Issue 9, 2013, Pages 2217-2224

  Lim, Wei Ling Florence ^a,b   Lam, Sin Man ^c   Shui, Guanghou ^d,g   Mondal, Alinda ^b   Ong, Daniel ^b   Duan, Xinrui ^d   Creegan, Rhona ^b   Martins, Ian J ^b   Sharman, Matthew J ^e   Taddei, Kevin ^b,f   Verdile, Giuseppe ^b,f   Wenk, Markus R ^d   Martins, Ralph Nigel ^a,b,f  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF TASMANIA   (Australia)

^f McCusker Foundation for Alzheimer's Disease Research Inc   (Australia)

^g INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

APOE KI mice; Glycerophospholipids; High cholesterol; High fat; Mass spectrometry; Oxysterols

Indexed keywords

14 DEMETHYLLANOSTEROL; 24 HYDROXYCHOLESTEROL; 7 HYDROXYCHOLESTEROL; 7 OXOCHOLESTEROL; APOLIPOPROTEIN; APOLIPOPROTEIN E EPSILON 3; APOLIPOPROTEIN E EPSILON 4; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; GLYCEROPHOSPHOLIPID; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; SPHINGOLIPID; SPHINGOMYELIN; SULFATIDE; UNCLASSIFIED DRUG;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID ANALYSIS; LIPID BRAIN LEVEL; LIPID DIET; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UPREGULATION;

AGING; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BRAIN; CHOLESTEROL ESTERS; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; GENE KNOCK-IN TECHNIQUES; GENOTYPE; LIPID METABOLISM; MALE; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; STEROL O-ACYLTRANSFERASE; SULFOGLYCOSPHINGOLIPIDS;

EID: 84878900198     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.03.012     Document Type: Article

References (52)

1. Bales K.R., Dodart J.C., DeMattos R.B., Holtzman D.M., Paul S.M. Apolipoprotein E, amyloid, and Alzheimer's disease. Mol. Interv. 2002, 2:363-375.
2. Bentley N.M., LaDu M.J., Rajan C., Getz G.S., Reardon C.A. Apolipoprotein Estructural requirements for the formation of SDS-stable complexes with beta-amyloid (1-40): the role of salt bridges. Biochem. J. 2002, 366:273-279.
3. Björkhem I., Heverin M., Leoni V., Meaney S., Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. 2006, 114:43-49.
4. Björkhem I., Lütjohann D., Diczfalusy U., Ståhle L., Ahlborg G., Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J.Lipid Res. 1998, 39:1594-1599.
5. Bligh E.G., Dyer W.J. Arapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
6. Brendza R.P., Bales K.R., Paul S.M., Holtzman D.M. Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. Mol. Psychiatry 2002, 7:132-135.
7. Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., Wenk M.R., Shui G., Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J.Biol. Chem. 2012, 287:2678-2688.
8. Chen X., Wagener J.F., Morgan D.H., Hui L., Ghribi O., Geiger J.D. Endolysosome mechanisms associated with Alzheimer's disease-like pathology in rabbits ingesting cholesterol-enriched diet. J.Alzheimers Dis. 2010, 22:1289-1303.
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
10. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J.Clin. Invest. 2008, 118:4002-4013.
11. DeKroon R., Robinette J.B., Hjelmeland A.B., Wiggins E., Blackwell M., Mihovilovic M., Fujii M., York J., Hart J., Kontos C., Rich J., Strittmatter W.J. APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt pathway via the phosphoinositol phosphatase SHIP2. Circ. Res. 2006, 99:829-836.
12. Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 2000, 106:1-29.
13. George A.J., Holsinger R.M.D., McLean C.A., Laughton K.M., Beyreuther K., Evin G., Masters C.L., Li Q.-X. APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol. Dis. 2004, 16:124-132.
14. Grimm M.O.W., Grimm H.S., Pätzold A.J., Zinser E.G., Halonen R., Duering M., Tshäpe J.-A., Strooper B.D., Müller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat. Cell Biol. 2005, 7:1118-1123.
15. Han X. Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:774-783.
16. Han X., Cheng H., Fryer J.D., Fagan A.M., Holtzman D.M. Novel role for apolipoprotein E in the central nervous system. J.Biol. Chem. 2003, 278:8043-8051.
17. Hartmann T. Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci. 2001, 24:S45-S48.
18. Heverin M., Bogdanovic N., Lütjohann D., Bayer T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B., Björkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J.Lipid Res. 2004, 45:186-193.
19. Holtzman D.M. Role of apoE/Aβ interactions in Alzheimer's disease: insights from transgenic mouse models. Mol. Psychiatry 2002, 7:132-135.
20. Hone E., Martins I.J., Fonte J., Martins R.N. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J.Alzheimers Dis. 2003, 5:1-8.
21. Huttunen H.J., Havas D., Peach C., Barren C., Duller S., Xia W., Frosch M.P., Hutter-Paier B., Windisch M., Kovacs D.M. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J.Neuropathol. Exp. Neurol. 2010, 69:777-788.
22. Jenner A.M., Lim W.L.F., Ng M.P.E., Wenk M.R., Shui G., Sharman M.J., Gandy S.E., Martins R.N. The effect of APOE genotype on brain levels of oxysterols in young and old human APOE e{open}2, e{open}3 and e{open}4 knock-in mice. Neuroscience 2010, 169:109-115.
23. Knouff C., Hinsdale M.E., Mezdour H., Altenburg M.K., Watanabe M., Quarfordt S.H., Sullivan P.M., Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J.Clin. Invest. 1999, 103:1529-1536.
24. Leoni V., Solomon A., Kivipelto M. Links between ApoE, brain cholesterol metabolism, tau and amyloid β-peptide in patients with cognitive impairment. Biochem. Soc. Trans. 2010, 38:1021-1025.
25. Lütjohann D., Papassotiropoulos A., Björkhem I., Locatelli S., Bagli M., Oehring R.D., Schlegel U., Jessen F., Rao M.L., Bergmann K.von, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J.Lipid Res. 2000, 41:195-198.
26. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
27. Manelli A.M., Stine W.B., Van Eldik L.J., LaDu M.J. ApoE and Aβ 1-42 interactions: effects of isoform and conformation on structure and function. J.Mol. Neurosci. 2004, 23:235-246.
28. Martins R.N., Clarnette R., Fisher C., Broe G.A., Brooks W.S., Montgomery P., Gandy S.E. ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. NeuroReport 1995, 6:1513-1516.
29. Miyazaki A., Saki M., Sakamoto Y., Horiuchi S. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. Curr. Opin. Invest. Drugs 2003, 4:1095-1099.
30. Mulder C., Wahlund L.-O., Teerlink T., Blomberg M., Veerhuis R., van Kamp G.J., Scheltens P., Scheffer P.G. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J.Neural Transm. 2003, 110:949-955.
31. Papassotiropoulos A., Lütjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Björkhem I., Bergmann K.von, Heun R. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J.Psychiatr. Res. 2002, 36:27-32.
32. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4471-4475.
33. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003, 9:94-101.
34. Poirier J., Davignon J. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
35. Puglielli L., Ellis B.C., Ingano L.A., Kovacs D.M. Role of acyl-coenzyme A: cholesterol acyltransferase activity in the processing of the amyloid precursor protein. J.Mol. Neurosci. 2004, 24:93-96.
36. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., Kovacs D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 2001, 3:905-912.
37. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
38. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
39. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 1996, 47:387-400.
40. Sharman M.J., Shui G., Fernandis A.Z., Lim W.L., Berger T., Hone E., Taddei K., Martins I.J., Ghiso J., Buxbaum J.D., Gandy S., Wenk M.R., Martins R.N. Profiling brain and plasma lipids in human APOE epsilon2, epsilon3, and epsilon4 knock-in mice using electrospray ionization mass spectrometry. J.Alzheimers Dis. 2010, 20:105-111.
41. Shie F.-S., Jin L.-W., Cook D.G., Leverenz J.B., LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice. NeuroReport 2002, 13:455-459.
42. Shui G., Cheong W.F., Jappar I.A., Hoi A., Xue Y.K., Fernandis A.Z., Tan B.K.H., Halliwell B., Wenk M.R. Derivatization-independent cholesterol analysis in crude lipid extracts by liquid chromatography/mass spectrometry: applications to a rabbit model for atherosclerosis. J.Chromatogr. A. 2011, 1218:4357-4365.
43. Shui G., Stebbins J.W., Lam B.D., Cheong W.F., Lam S.M., Gregoire F., Kusonoki J., Wenk M.R. Comparative plasma lipidome between human and cynomolgus monkey: are plasma polar lipids good biomarkers for diabetic monkeys?. PLoS ONE 2011, 6:e19731.
44. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
45. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 1996, 19:53-77.
46. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allelle enhances dist-induced hypercholesterolemia and atherosclerosis. J.Biol. Chem. 1997, 272:17972-17980.
47. Sullivan P.M., Mezdour H., Quarfordt S.H., Maeba N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting fron gene replacement of mouse ApoE with human Apoe*2. J.Clin. Invest. 1998, 102:130-135.
48. Vos J.P., Lopes-Cardozo M., Gadella B.M. Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1994, 1211:125-149.
49. Wenk M.R. The emerging field of lipidomics. Nature Rev. Drug Discov. 2005, 4:594-610.
50. Wenk M.R. Lipidomics: new tools and applications. Cell 2010, 143:888-895.
51. Wisniewski T., Golabek A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 1993, 192:359-365.
52. Zannis V.I., Breslow J.L., Utermann G., Mahley R.W., Weisgraber K.H., Havel R.J., Goldstein J.L., Brown M.S., Schonfeld G., Hazzard W.R., Blum C. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J.Lipid Res. 1982, 23:911-914.